G Mangili

Summary

Affiliation: San Raffaele Scientific Institute
Country: Italy

Publications

  1. pmc Long-term follow-up is crucial after treatment for granulosa cell tumours of the ovary
    G Mangili
    Gynecology Department, San Raffaele Scientific Institute, Via Olgettina 60, 20132 Milan, Italy
    Br J Cancer 109:29-34. 2013
  2. doi Unraveling the two entities of endometrioid ovarian cancer: a single center clinical experience
    Giorgia Mangili
    Obstetrics and Gynecology Unit, San Raffaele Scientific Institute, Milano, Italy
    Gynecol Oncol 126:403-7. 2012
  3. pmc Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study
    Sandro Pignata
    Istituto Nazionale Tumori, Napoli, Italy
    BMC Cancer 8:252. 2008
  4. doi Outcome and risk factors for recurrence in malignant ovarian germ cell tumors: a MITO-9 retrospective study
    Giorgia Mangili
    Gynecology Department, IRCCS San Raffaele Hospital, Milan
    Int J Gynecol Cancer 21:1414-21. 2011
  5. doi Is surgical restaging indicated in apparent stage IA pure ovarian dysgerminoma? The MITO group retrospective experience
    G Mangili
    Gynecology Department, I R C C S San Raffaele Hospital, Milan, Italy
    Gynecol Oncol 121:280-4. 2011
  6. doi Is adjuvant chemotherapy indicated in stage I pure immature ovarian teratoma (IT)? A multicentre Italian trial in ovarian cancer (MITO-9)
    G Mangili
    Gynecology Department, IRCCS San Raffaele Hospital, Milan, Italy
    Gynecol Oncol 119:48-52. 2010
  7. ncbi Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling
    G Mangili
    IRCCS Ospedale San Raffaele, Obstetrics and Gynecology Department, Milan, Italy
    Gynecol Oncol 108:332-5. 2008
  8. pmc Paclitaxel and concomitant radiotherapy in high-risk endometrial cancer patients: preliminary findings
    Giorgia Mangili
    Gynecology Department, San Raffaele Hospital, Milan, Italy
    BMC Cancer 6:198. 2006
  9. ncbi An unusual admixture of neoplastic and metaplastic lesions of the female genital tract in the Peutz-Jeghers Syndrome
    Giorgia Mangili
    Division of Gynecology and Obstetrics, University Vita e Salute, S Raffaele Hospital, Milan, Italy
    Gynecol Oncol 92:337-42. 2004
  10. ncbi Sarcoidosis mimicking metastatic gynaecological malignancies: a diagnostic and therapeutic challenge?
    P Mapelli
    Department of Nuclear Medicine, San Raffaele Scientific Institute, Milan, Italy
    Rev Esp Med Nucl Imagen Mol 32:314-7. 2013

Collaborators

Detail Information

Publications26

  1. pmc Long-term follow-up is crucial after treatment for granulosa cell tumours of the ovary
    G Mangili
    Gynecology Department, San Raffaele Scientific Institute, Via Olgettina 60, 20132 Milan, Italy
    Br J Cancer 109:29-34. 2013
    ....
  2. doi Unraveling the two entities of endometrioid ovarian cancer: a single center clinical experience
    Giorgia Mangili
    Obstetrics and Gynecology Unit, San Raffaele Scientific Institute, Milano, Italy
    Gynecol Oncol 126:403-7. 2012
    ..We have investigated clinical and histologic features of endometriosis-associated endometrioid ovarian cancer using an institutional retrospective database...
  3. pmc Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study
    Sandro Pignata
    Istituto Nazionale Tumori, Napoli, Italy
    BMC Cancer 8:252. 2008
    ..The aim of this study was to evaluate, retrospectively, the activity of chemotherapy in patients with platinum sensitive recurrent mucinous ovarian cancer...
  4. doi Outcome and risk factors for recurrence in malignant ovarian germ cell tumors: a MITO-9 retrospective study
    Giorgia Mangili
    Gynecology Department, IRCCS San Raffaele Hospital, Milan
    Int J Gynecol Cancer 21:1414-21. 2011
    ..This study aimed to investigate the outcome of patients with malignant ovarian germ cell tumors (MOGCTs) and to define the risk factors for recurrence...
  5. doi Is surgical restaging indicated in apparent stage IA pure ovarian dysgerminoma? The MITO group retrospective experience
    G Mangili
    Gynecology Department, I R C C S San Raffaele Hospital, Milan, Italy
    Gynecol Oncol 121:280-4. 2011
    ..The aim of study was to evaluate the outcome of IA POD patients with incomplete surgical staging in order to define the proper management...
  6. doi Is adjuvant chemotherapy indicated in stage I pure immature ovarian teratoma (IT)? A multicentre Italian trial in ovarian cancer (MITO-9)
    G Mangili
    Gynecology Department, IRCCS San Raffaele Hospital, Milan, Italy
    Gynecol Oncol 119:48-52. 2010
    ..Nevertheless the use of chemotherapy in stage IA G2-3 and IB-IC is controversial. The aim of this study was to evaluate the outcome of patients with IT in order to define the role of chemotherapy in stage I disease...
  7. ncbi Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling
    G Mangili
    IRCCS Ospedale San Raffaele, Obstetrics and Gynecology Department, Milan, Italy
    Gynecol Oncol 108:332-5. 2008
    ..Different therapies have been proposed to alleviate PPE onset. We performed a prospective study to evaluate preventive strategies to reduce PPE incidence in patients treated for gynecologic cancers...
  8. pmc Paclitaxel and concomitant radiotherapy in high-risk endometrial cancer patients: preliminary findings
    Giorgia Mangili
    Gynecology Department, San Raffaele Hospital, Milan, Italy
    BMC Cancer 6:198. 2006
    ..Radiotherapy (RT) alone does not seem to improve overall survival. We investigated whether concomitant Paclitaxel (P) and RT gave better clinical results...
  9. ncbi An unusual admixture of neoplastic and metaplastic lesions of the female genital tract in the Peutz-Jeghers Syndrome
    Giorgia Mangili
    Division of Gynecology and Obstetrics, University Vita e Salute, S Raffaele Hospital, Milan, Italy
    Gynecol Oncol 92:337-42. 2004
    ..Patients with PJS have an increased risk for breast, gastrointestinal and female genital tract cancers...
  10. ncbi Sarcoidosis mimicking metastatic gynaecological malignancies: a diagnostic and therapeutic challenge?
    P Mapelli
    Department of Nuclear Medicine, San Raffaele Scientific Institute, Milan, Italy
    Rev Esp Med Nucl Imagen Mol 32:314-7. 2013
    ..Furthermore, the clinical relevance of making a differential diagnosis between gynaecological cancer recurrence and granulomatous disorder is given specific mention...
  11. ncbi Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer
    G Mangili
    Department of Gynaecology and Obstetrics, Scientific Institute San Raffaele, Milan, Italy
    Eur J Nucl Med Mol Imaging 34:658-66. 2007
    ..The aims of this study were to compare CT with PET/CT results in patients with suspected ovarian cancer recurrence and to assess the impact of the PET/CT findings on their clinical management...
  12. ncbi Concomitant radiotherapy and paclitaxel for high-risk endometrial cancer: first feasibility study
    L Frigerio
    Department of Gynecologic and Obstetrics, S. Raphael Hospital, University of Milan, Milan, Italy
    Gynecol Oncol 81:53-7. 2001
    ..CONCLUSIONS: Concomitant P and RT is safe and acceptable treatment in patients with HREC. Prospective clinical studies are necessary to evaluate the benefits of this regimen for the long-term survival rate...
  13. ncbi Response and toxicity to topotecan in sensitive ovarian cancer cases with small residual disease after first-line treatment with carboplatinum and paclitaxel
    G Bolis
    I(a) Clinica Ostetrico Ginecologica, , Milan, Italy
    Gynecol Oncol 80:13-5. 2001
    ..8% (SE 6.4). CONCLUSION: This study indicates that sequential therapy with carboplatin plus paclitaxel followed by topotecan, all given at standard doses, is feasible and provides favorable response rates...
  14. doi Role of 18F-FDG PET in the management of gestational trophoblastic neoplasia
    P Mapelli
    Department of Nuclear Medicine, San Raffaele Scientific Institute, Milan, Italy
    Eur J Nucl Med Mol Imaging 40:505-13. 2013
    ..The effect of FDG PET and combined PET/CT on the management of patients with GTN was also evaluated comparing the differences between standard treatments based on conventional imaging and alternative treatments based on PET...
  15. doi Positron emission tomography/computed tomography introduction in the clinical management of patients with suspected recurrence of ovarian cancer: a cost-effectiveness analysis
    M Mansueto
    Institute for Bioimaging and Molecular Physiology, National Research Council, University of Milano Bicocca and San Raffaele Hospital Scientific Institute, Milan, Italy
    Eur J Cancer Care (Engl) 18:612-9. 2009
    ..50-433.00 euro). Positron emission tomography/computed tomography introduction in this population is cost-effective and allowed to redirect the clinical management of patients towards more appropriate therapeutic choices...
  16. ncbi Palliative care for intestinal obstruction in recurrent ovarian cancer: a multivariate analysis
    G Mangili
    Division of Gynecology and Obstetrics, University Vita e Salute, S Raffaele Hospital, Milano, Italy
    Int J Gynecol Cancer 15:830-5. 2005
    ..Survival was significantly longer in the surgical group, and surgical palliation should be considered first in patients with good performance status...
  17. doi Comparison of optimal cytoreduction rates in emergency versus non-emergency admissions for advanced ovarian cancer: a multi-institutional study
    G Mangili
    Division of Gynecologic Oncology, San Raffaele Hospital, Milan, Italy
    Eur J Surg Oncol 39:906-11. 2013
    ....
  18. ncbi Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer
    G Bolis
    I(a) Clinica Ostetrico Ginecologica, , Milan, Italy
    Gynecol Oncol 81:3-9. 2001
    ..Toxicity, particularly hematological, was more relevant in women treated with the multiagent schedule...
  19. ncbi [18F]fluorodeoxyglucose positron emission tomography as a useful indicator of metastatic gestational trophoblastic tumor: preliminary results in three patients
    S Sironi
    University of Milano Bicocca, Milan, Italy
    Gynecol Oncol 91:226-30. 2003
    ..The goal of this study was to evaluate the usefulness of positron emission tomography with [(18)F]fluorodeoxyglucose ([(18)F]FDG-PET) in detecting metastases in patients with gestational trophoblastic tumor (GTTs)...
  20. ncbi Metastatic placental site trophoblastic tumor. Report of a case with complete response to chemotherapy
    G Mangili
    Department of Obstetrics and Gynecology, Ospedale San Raffaele, Via Olgettina 60, 20100 Milan, Italy
    J Reprod Med 46:259-62. 2001
    ..CONCLUSION: Treatment with multiagent chemotherapy can produce long-term remission, even in patients with metastatic PSTT...
  21. doi Transvaginal ultrasound predicts delayed response to chemotherapy and drug resistance in stage I low-risk trophoblastic neoplasia
    P Cavoretto
    IRCCS San Raffaele Hospital, Obstetrics and Gynecology Department, Vita Salute University, Milan, Italy
    Ultrasound Obstet Gynecol 40:99-105. 2012
    ..The aim of this study was to identify low-risk non-metastatic patients with gestational trophoblastic neoplasia (GTN) who can achieve resolution by continuing MTX treatment despite a transient hCG plateau...
  22. doi The role of DNA ploidy in postoperative management of stage I endometrial cancer
    G Mangili
    Division of Gynecology and Obstetrics, IRCCS San Raffaele Hospital, University of Milan, Milan, Italy
    Ann Oncol 19:1278-83. 2008
    ..Decision is on the basis of traditional prognostic factors. We report our experience in which ploidy has found to play a role in clinical practice since 1999...
  23. ncbi Hereditary surfactant protein B deficiency resulting from a novel mutation
    M Somaschini
    Divisione di Patologia Neonatale, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Intensive Care Med 26:97-100. 2000
    ..Hereditary SP-B deficiency is a rare, newly diagnosable and probably under-recognized disease, which should be suspected in term newborn infants with unexplained respiratory failure...
  24. ncbi Advanced ovarian carcinoma: usefulness of [(18)F]FDG-PET in combination with CT for lesion detection after primary treatment
    M Picchio
    IBFM CNR, University of Milano Bicocca, University of Vita Salute, Institute H San Raffaele, Milan, Italy
    Q J Nucl Med 47:77-84. 2003
    ..To determine the additional value of [(18)F]FDG-PET in combination with computed tomography (CT) over CT used alone, for evaluating ovarian cancer patients after primary treatment...
  25. ncbi Primary stage I-IIE non-Hodgkin's lymphoma of uterine cervix and upper vagina: evidence for a conservative approach in a study on three patients
    Elisabetta Garavaglia
    Division of Gynecology and Obstetrics, University Vita e Salute, S Raffaele Hospital, V Olgettina 60, 20132 Milan, Italy
    Gynecol Oncol 97:214-8. 2005
    ..However, these organs are rarely the site of origin of this type of neoplasia. Because of the rarity of primary genital tract lymphomas, a standard treatment has not been defined...
  26. ncbi Paclitaxel 175 or 225 mg per meters squared with carboplatin in advanced ovarian cancer: a randomized trial
    Giorgio Bolis
    Prima Clinica Ostetrico Ginecologica, Universita di Milano, Milan, Italy
    J Clin Oncol 22:686-90. 2004
    ..To analyze the effect of different doses of paclitaxel with fixed doses of carboplatin in the treatment of ovarian cancer...